Vasodilator therapy of cardiac failure (second of two parts).

Bronchodilator therapy (second of two parts).

Drug therapy: antiplatelet therapy (second of two parts).

Gastrin (second of two parts).

Histamine (second of two parts).

Noninvasive cardiac diagnosis (second of three parts).

Lung defense mechanisms (second of two parts).

Renal transplantation (second of two parts).

Clinical pharmacokinetics (second of two parts).

Polymyositis and dermatomyositis (second of two parts).

Clinical pharmacology of oral antidiabetic agents (second of two parts).

The pathogenesis of atherosclerosis (second of two parts).

Catecholamines and neurologic diseases (second of two parts).

Oxygen-dependent microbial killing by phagocytes (second of two parts).

Drug therapy. Drug allergy (second of three parts).

The role of vasodilator therapy in heart failure.

Chronic vasodilator therapy with flosequinan in congestive heart failure.

Future directions in vasodilator therapy for heart failure.

Vasodilator therapy and survival in chronic congestive heart failure.

Dialytic therapy for irreversible uremia (first of two parts).

Drug therapy. Clinical Pharmacokinetics (first of two parts).

Regulation of respiration: (second of three parts).

Nerve growth factor (second of three parts).

Chlamydial infections (second of three parts).

Enzyme induction (second of three parts).

Suggest Documents

Bronchodilator therapy (second of two parts).

Drug therapy: antiplatelet therapy (second of two parts).

Gastrin (second of two parts).

Histamine (second of two parts).

Noninvasive cardiac diagnosis (second of three parts).

Lung defense mechanisms (second of two parts).

Renal transplantation (second of two parts).

Clinical pharmacokinetics (second of two parts).

Polymyositis and dermatomyositis (second of two parts).

Clinical pharmacology of oral antidiabetic agents (second of two parts).

The pathogenesis of atherosclerosis (second of two parts).

Catecholamines and neurologic diseases (second of two parts).

Oxygen-dependent microbial killing by phagocytes (second of two parts).

Drug therapy. Drug allergy (second of three parts).

The role of vasodilator therapy in heart failure.

Chronic vasodilator therapy with flosequinan in congestive heart failure.

Future directions in vasodilator therapy for heart failure.

Vasodilator therapy and survival in chronic congestive heart failure.

Dialytic therapy for irreversible uremia (first of two parts).

Drug therapy. Clinical Pharmacokinetics (first of two parts).

Regulation of respiration: (second of three parts).

Nerve growth factor (second of three parts).

Chlamydial infections (second of three parts).

Enzyme induction (second of three parts).

Vasodilator therapy of cardiac failure (second of two parts).

Recommend Documents

Follow Us